

Table SVII. Heterogeneity test results.

ID outcome	Outcome	Exposure	Method	Q	Q _{df}	Q P-value
finngen_R12_CD2_INSITU_CERVIX_UTERI_EXALLC	Carcinoma <i>in situ</i> of cervix uteri (controls excluding all cancers) id:finngen_R12_CD2_INSITU_CERVIX_UTERI_EXALLC	HMGN1	MR Egger	0.473791 0496725 05	2	0.789073722317714
			Inverse variance weighted	3.137111 6087792 9	3	0.370964551313898
		TKT	MR Egger	2.364194 8410587 8	2	0.306634921280399
			Inverse variance weighted	4.853632 8601454 6	3	0.182834011712564
		ZYG	MR Egger	1.649045 8454585 2	2	0.438444114298767
			Inverse variance weighted	1.785590 9396616 1	3	0.618075517572664

HMGN1, high-mobility group nucleosome-binding protein 1; TKT, transketolase; ZYG, zyxin; MR, Mendelian randomization.

Table SVIII. Results of the horizontal pleiotropy test of HMGN1.

ID exposure	ID outcome	Outcome	Exposure	Egger intercept	SE	P-value
finngen_R12_CD2_INSITU_CERVIX_UTERI_EXAL_LC	finngen_R12_CD2_INSITU_CERVIX_UTERI_EXAL_LC	Carcinoma in situ of cervix uteri (controls excluding all cancers) id:finngen_R12_CD2_INSITU_CERVIX_UTERI_EXAL_LC	HMGN1	0.194595245582029	0.119239598342221	0.244274484127859

HMGN1, high-mobility group nucleosome-binding protein 1.